EVALUATION OF OPTIMAL HIGH DENSITY CHOLESTEROL VALUE IN COHORT OF ALMOST HEALTHY MEN 40-59 YEARS OLD (BY THE DATA OF 30-YEAR PROSPECTIVE OBSERVATION)

Material and methods. Totally 2177 men studied at the age 40-59 y., that were 72,3% of all inhabitants of Chelyabinsk districts. As healthy were 398 marked, and for further study 174 persons selected (50%), of 40 refused to participate. During 30 years, we followed 134 men. All participants underwent the assessments of total cholesterol, low- density cholesterol, HDL, other biochemical parameters. As endpoint, we regarded the death. Statistics was done with Excel, STATISTICA 10.0, SPSS 17.0 software. We measured mortality rates with 95% confidence intervals. Survival equation by different levels of HDL in the range 0,3-2,0 mmol/l was done by the Kaplan-Meyer method. Confidence rows of survival were built-up with non-parametric criteria of Kolmogorov- Smirnov. The regression dependence was studied for the life duration of an individ and the level of HDL using Cox model. Results. Thirty-year mortality equations in almost healthy men of 40-59 y.o. demonstrate clear dependence on the HDL level. The level of HDL 1,7 mmol/l is associated with the most positive parameters of 30-year survival. The mentioned HDL level is desirable for this category of persons.

Conclusion. The survival equation demonstrates the value of an exposition of the set level of HDL, and the beginning, duration and cessation of statistically relevant increase of survival comparing to lower values of the studied parameter.

1. Ray KK, Kastelein JJ, Boekholdt SM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014; 35(15):960-8. doi:10.1093/eurheartj/ehu 107.

2. Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor

3. adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vase Health Risk Manag 2013; 9:617-70. doi: 10.2147/VHRM.S37119.

4. Jameson K, Amber V, D'Oca K, et al. Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care — a retrospective database study. Int J Clin Pract 2013 Dec; 67(12): 1228-37. doi: 10.1111/ijcp. 12238.

5. Stone N J, Robinson JG, Lichtenstein AH, et aJ. ACC/AHA Prevention Guideline: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults/ A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S1-S45. Published online before print November 12, 2013, doi:10.1161/01.cir.0000437738. 63853.7a.

6. Kavousi M, Leening MJ, Nanchen D, et al. Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort. JAMA 2014; 9;311(14):1416-23. doi:10.1001/jama.2014.2632.

7. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 2011; 32: 1769-818.

8. Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis 1988; 8(3): 207-11.

9. Tot PP, Maky KK. Disorders of lipid metabolism. Ed W Kucharchuk. M.:"GEOTAR-Media", 2010: 272p. Russian (Тот П. П., Мэки К. К. Нарушения липидного обмена: пер. с англ./под ред. В. В. Кухарчука. М.: Изд-во ГЭОТАР-Медиа, 2010.272 с).

10. Kucharchuk W. Cardiology: clinical guidelines Ed. YJ N. Belenkov, RG Oganov. 2-ed., corr. and suppl. M.:"GEOTAR-Media", 2009: 205-30. Russian (Кухарчук В. В. Кардиология: Клинические рекомендации/ под ред.Ю.Н. Беленкова, Р. Г. Оганова 2-е изд. испр. и доп. М.:ТЭОТАР-Медиа", 2009;

11. -30).

12. Belov W, Menschikov АА. Survival rate functions in cohorts of men aged 40-59 depending on presence of arterial hypertension and old myocardial infarction at various concentration of HDL-C (according to 30-year prospective study). Atherosclerosis and dislipidemias 2013; 3(12): 25-35. Russian (Белов В. В., Меньшиков А. А. Функции выживаемости в когортах мужчин 40-59 лет в зависимости от наличия артериальной гипертонии и перенесенного инфаркта миокарда при различных концентрациях холестерина липопротеинов высокой плотности (поданным 30-летнего наблюдения). Атеросклероз и дислипидемии 2013; 12(3): 25-35).

13. Lang N, SecicV. How То Report Statistics in Medicine. Annotated Guidelines for Authors, Editors, and Reviewers. M.: Prakticheskaja medicina; 2011. 480 p. Russian (ЛангТ.А., СесикМ. Как описывать статистику в медицине. Аннотированное руководство для авторов, редакторов и рецензентов. Пер. с англ. М: Практическая медицина; 2011. 480 с).

14. Diagnostics and correction of lipid disorders prevention and treatment of atherosclerosis: Russian recommendations (V revision). Russ J Cardiol, 2012; 4 (96), Suppl. 1: 32 p. Russian (Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза: российские рекомендации (V пересмотр). Российский кардиологический журнал, 2012; 4 (96), Приложение 1:32 с).

15. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.

16. Haney EM, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipid disorders in children and adolesents: systematic evidence review for the US Preventive Services Task Force Pediatrics. 2007 Jul;120(1):e189-214.

17. Klose G, Beil FU, Dieplinger H, et al. New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. Wien Klin Wochenschr 2014 Mar;126(5-6): 169-175. doi: 10.1007/S00508-014-0513-9.

18. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013 May; 34(17): 1279-91. doi: 10.1093/eurheartj/eht055.